Published in BJU Int on September 08, 2008
Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol (2012) 1.19
Predictive factors of Gleason score upgrading in localized and locally advanced prostate cancer diagnosed by prostate biopsy. Korean J Urol (2010) 1.01
Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. Eur Radiol (2014) 0.89
PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol (2010) 0.87
Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2014) 0.83
Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch (2015) 0.82
Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer. Can Urol Assoc J (2013) 0.81
Is small prostate volume a predictor of Gleason score upgrading after radical prostatectomy? Yonsei Med J (2013) 0.80
Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer. J Korean Med Sci (2011) 0.79
Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. Int J Clin Exp Pathol (2012) 0.79
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget (2016) 0.78
Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter? Korean J Urol (2015) 0.78
Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. Biomed Res Int (2014) 0.77
Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study. World J Urol (2010) 0.77
Soluble interleukin-6 receptor to interleukin-6 (sIL‑6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. Oncol Lett (2011) 0.77
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol (2015) 0.77
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making. Clin Interv Aging (2014) 0.77
Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores. World J Urol (2014) 0.76
Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy. Asian J Androl (2016) 0.76
Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int (2014) 0.75
GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. World J Oncol (2015) 0.75
Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland. World J Urol (2013) 0.75
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy. Curr Urol (2017) 0.75
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation (2004) 4.13
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol (2010) 3.05
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol (2009) 2.75
Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology (2011) 2.68
Laparoscopic radical nephrectomy: incorporating advantages of hand assisted and standard laparoscopy. J Urol (2003) 2.61
Parenchymal volume preservation and ischemia during partial nephrectomy: functional and volumetric analysis. Urology (2013) 2.59
General protein diffusion barriers create compartments within bacterial cells. Cell (2012) 2.48
Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int (2011) 2.41
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol (2011) 2.38
Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer (2002) 2.33
Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation (2002) 2.31
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol (2007) 2.31
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol (2009) 2.18
Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol (2009) 2.13
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology (2011) 2.12
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int (2011) 2.12
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology (2011) 2.07
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology (2010) 2.04
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol (2008) 2.02
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys (2002) 2.01
Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol (2009) 2.00
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res (2003) 1.95
The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol (2010) 1.94
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol (2008) 1.93
Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int (2011) 1.88
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology (2011) 1.78
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology (2006) 1.75
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A (2002) 1.73
Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol (2009) 1.73
Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology (2008) 1.71
Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.71
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys (2004) 1.64
Office based flexible cystoscopy may be less painful for men allowed to view the procedure. J Urol (2007) 1.62
Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair. J Am Coll Surg (2009) 1.59
Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol (2003) 1.59
Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology (2010) 1.58
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. Retrovirology (2010) 1.57
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate (2014) 1.56
Risk of infection after midurethral synthetic sling surgery: are postoperative antibiotics necessary? Urology (2010) 1.55
Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol (2008) 1.53
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology (2010) 1.53
Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS One (2011) 1.52
Inclusion of erectile domain to UPOINT phenotype does not improve correlation with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome. Urology (2011) 1.51
Determining the course of the dorsal nerve of the clitoris. Urology (2008) 1.50
Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst (2009) 1.49
Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol (2008) 1.49
Transplant nephrectomy after allograft failure is associated with allosensitization. Urology (2011) 1.47
Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int (2010) 1.46
Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. Int J Urol (2011) 1.46
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet (2006) 1.46